

1 **Influenza vaccine effectiveness against influenza-associated hospitalizations in children,**
2 **Hong Kong, November 2023 to June 2024**

3

4 So-Lun Lee^{1,2*}, Mike Y. W. Kwan^{3*}, Caitriona Murphy^{4*}, Eunice L. Y. Chan¹, Joshua S. C.

5 Wong³, Sheena G. Sullivan^{5,6}, Malik Peiris^{4,7}, Benjamin J. Cowling^{4,8}

6

7 *Joint first authors with equal contribution

8

9 **Affiliations**

10 1. Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The

11 University of Hong Kong, Hong Kong Special Administrative Region, China

12 2. Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong

13 Special Administrative Region, China

14 3. Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong

15 Kong Special Administrative Region, China

16 4. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of

17 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong

18 Special Administrative Region, China

19 5. School of Clinical Sciences, Monash University, Melbourne, Australia

20 6. Department of Epidemiology, University of California, Los Angeles, USA

21 7. Centre for Immunology & Infection, Hong Kong Science and Technology Park, New

22 Territories, Hong Kong Special Administrative Region, China

23 8. Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park,

24 New Territories, Hong Kong Special Administrative Region, China

25

26 Corresponding author: bcowling@hku.hk

27

28 Word count (abstract): 150

29 Word count (main text): 1,990

30

31 **ABSTRACT**

32 We conducted a test negative study from November 2023 to June 2024, enrolling 4,367
33 children hospitalized with acute respiratory illness in Hong Kong. Among the children who
34 tested negative for influenza virus and SARS-CoV-2, 56.8% had received influenza
35 vaccination. Between November 2023 and March 2024, influenza A(H3N2) predominated
36 and the VE against influenza A(H3N2) was estimated as 55% (95% CI: 29.6%, 71.8%). VE
37 point estimates were higher for younger children than older children. In February to June
38 2024 influenza A(H1N1) predominated and VE against influenza A(H1N1) was 54% (95% CI:
39 33%, 69%) during this period. Influenza B circulated at low intensity throughout the 2023/24
40 season and VE against influenza B was 66% (95% CI: 42%, 80%). Since its introduction in
41 2018/19 the school-based influenza vaccination program has substantially increased vaccine
42 uptake in children in Hong Kong and prevented influenza-associated hospitalizations.

43

44 INTRODUCTION

45 Annual influenza vaccination is recommended for all individuals over 6 months of age. In
46 Hong Kong, a school-based influenza vaccination program began in 2018 and progressively
47 expanded to include children up to 18 years of age by 2022/23 [1]. The program for the
48 2023/24 season covered 70% of secondary schools, 95% of primary schools and 80% of
49 kindergartens and childcare centers [2]. Children up to 6 years of age are also able to
50 receive free or subsidized influenza vaccines via primary care physicians. Most vaccines
51 administered in Hong Kong are inactivated split virion vaccines, and a small proportion of
52 vaccinated children receive live attenuated influenza vaccines. The northern hemisphere
53 vaccine formulation is used.

54

55 We have been monitoring influenza vaccine effectiveness (VE) against influenza-associated
56 hospitalizations in children since 2009 [3,4]. Influenza was absent from Hong Kong between
57 March 2020 and February 2023, when various public health and social measures were being
58 used to control COVID-19 transmission [5]. Influenza circulation resumed in March 2023 and
59 several influenza A epidemics have occurred since then [6,7], accompanied by steady
60 circulation of influenza B. Here, we report estimates of influenza VE for the 2023/24 season
61 including the second waves of A(H3N2) and A(H1N1) since the COVID-19 pandemic.

62

63 METHODS

64 *Study design*

65 We implemented a test-negative design study among children hospitalized with recent-
66 onset acute respiratory illness at the Queen Mary Hospital on Hong Kong Island and the
67 Princess Margaret Hospital in Kowloon. Based on their catchment populations, these two

68 hospitals cover approximately 14% of all pediatric hospitalizations in Hong Kong. Eligible
69 children were aged 6 months to 17 years with at least one respiratory symptom and a fever
70 measuring $\geq 38^{\circ}\text{C}$. Information on influenza vaccination status was collected by interviewing
71 parents or legal guardians using a standard questionnaire, and cross-checking responses
72 with medical records. Relevant demographic and clinical information were obtained by
73 chart review. At the time, all children admitted with respiratory symptoms were routinely
74 tested on admission for influenza A and B virus, SARS-CoV-2 and other common respiratory
75 viruses using an in-house multiplex PCR assay, and the FilmArray Respiratory Panel
76 (BioFire/bioMérieux, Salt Lake City, UT).

77

78 Children were considered vaccinated if they had been fully vaccinated since 1 August 2023
79 and at least 2 weeks prior to hospitalization. Children were fully vaccinated if they were
80 aged 9 years or older and had received one vaccine dose or, for children aged <9 years, if
81 they had received two doses of influenza vaccine one month apart or one dose with a
82 previous dose prior to August 2023 [8]. Because the second vaccine dose for infants is
83 recommended at 7 months of age, we restricted enrolment to children aged at least 9
84 months of age. We reviewed influenza virus sequence data from GISAID to identify
85 circulating virus clades during the study period. Our study protocol was approved by the
86 Institutional Review Board of the Hospital Authority Hong Kong West Cluster and the
87 Hospital Authority Kowloon West Cluster Research Ethics Committee. Verbal consent was
88 obtained from the parents or legal guardians of participants.

89

90 ***Statistical analysis***

91 We determined relevant epidemic periods for influenza A subtypes by identifying
92 contiguous periods during which there were at least 5 hospitalizations with that subtype
93 each week. We used conditional logistic regression models to estimate conditional odds
94 ratios for influenza positivity by vaccination status, adjusting for age (quadratic term), sex,
95 prior year's vaccination status and the presence of underlying medical conditions,
96 conditioning by two-week periods of calendar time. VE was estimated as one minus the
97 adjusted conditional odds ratio, multiplied by 100%. For each type/subtype analysis, VE
98 estimates were made overall and stratified by age, and children were excluded from each
99 control group if they tested negative for the type/subtype in question but positive for a
100 different influenza type/subtype. Children testing negative for influenza but positive for
101 SARS-CoV-2 were also excluded from each control group given the potential correlation
102 between receipt of influenza vaccination and SARS-CoV-2 vaccination [9]. Statistical analyses
103 were conducted in R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria).

104

105 **RESULTS**

106 During our study period, there was an epidemic of influenza A(H3N2) in November 2023 to
107 early 2024 and then an influenza A(H1N1) epidemic in the spring of 2024. Influenza B
108 circulated throughout the period with no distinct epidemic. Our focus in the following
109 analyses is on estimation of influenza VE against hospitalizations associated with: (1)
110 influenza A(H3N2) in the period November 2023 through March 2024; (2) influenza A(H1N1)
111 in the period February 2024 through June 2024; (3) influenza B during the overall study
112 period of November 2023 to June 2024 (Figure 1).

113

114 In total from 16 November 2023 to 12 June 2024, 4565 children were enrolled with acute
115 respiratory illness. Among the influenza-negatives, there were 198 who tested positive for
116 SARS-CoV-2 and were removed from analyses. Of the remaining 4367 children aged 9
117 months to 17 years, 709 (16%) tested positive for influenza. There were 2311 children who
118 reported receipt of influenza vaccination (Table 1), including 2247 (97%) who received
119 quadrivalent inactivated influenza vaccine and 51 (2%) that received quadrivalent live
120 attenuated vaccine. Of the remaining 13 children, 8 received a trivalent vaccine and 5
121 received an unknown vaccination type.

122

123 In the influenza A(H3N2) epidemic period, sequence data from GISAID indicated that a
124 majority of circulating viruses fell in the 2a.3a.1 clade. These viruses are antigenically drifted
125 from the 2023/24 northern hemisphere vaccine virus A/Darwin/9/2021(H3N2) and are more
126 similar to the A/Thailand/8/2022, the vaccine virus recommended for the 2024 southern
127 hemisphere vaccine. During these 17 weeks, 178 children tested positive for influenza
128 A(H3N2), while 1941 tested negative for influenza A(H1N1) and B, and SARS-CoV-2. VE
129 against influenza A(H3N2) was estimated to be 55% (95% confidence interval, CI: 30%, 72%)
130 (Table 2). VE estimates were higher for younger children (Table 1).

131

132 Sequence data for the influenza A(H1N1) epidemic from February to June 2024 indicated
133 the predominant circulating clade was 5a.2a, similar to the A/Victoria/4897/2022 influenza
134 A(H1N1) vaccine virus used in the 2023/24 northern hemisphere vaccine. During this period,
135 287 children tested positive for influenza A(H1N1). Estimated VE against influenza A(H1N1)
136 was 54% (95% CI: 33%, 69%) overall, and higher in the younger children. Over the whole
137 study period, 164 children were hospitalized with influenza B. The estimated VE against

138 influenza B was 66% (95% CI: 42%, 80%) overall, and higher for children 9 months to 3 years
139 (Table 1).

140

141 **DISCUSSION**

142 We estimated VE against influenza A(H3N2) of 55% (95% CI: 30%, 72%) which was the same
143 as the VE estimate of 55% (95% CI: 20%, 74%) for children 0-17 years reported by the US
144 New Vaccine Surveillance Network (NVSN) for outpatients [10]. We are not aware of other
145 published VE estimates against A(H3N2) specifically for children for the 2023/24 season. Our
146 estimates are slightly higher than the interim all-age VE point estimates against influenza
147 A(H3N2) of 30% (95% CI: -3%, 54%) in primary care and 14% (95% CI: -32%, 43%) in hospitals
148 in Europe [11].

149

150 Our observed VE point estimate for A(H3N2) was also higher than in the preceding 2022/23
151 season in Hong Kong, which had the same vaccine formulation for influenza A(H3N2) and
152 where the circulating influenza A(H3N2) also fell in the 2a.3a.1 clade [7]. Waning immunity
153 was postulated to be a contributing factor to the low VE point estimate in 2022/23 against
154 influenza A(H3N2) (VE: 14%; 95% CI: -29%, 43%), as that epidemic peaked more than six
155 months after the usual vaccination period from October and November [7]. In contrast the
156 A(H3N2) epidemic in 2023/24 occurred soon after vaccines had been administered.

157

158 The VE against influenza A(H1N1) in Hong Kong was estimated as 54% (95% CI: 33%, 69%),
159 which was slightly lower than the estimate reported from the NVSN for inpatient children 6
160 months to 17 years (VE: 60%; 95% CI: 32%, 77%) [10] and from Canada for children 1-19
161 years (VE: 68; 95% CI: 42%, 83%) [12], and substantially lower than the VE reported among

162 children in primary care in Europe (VE: 85%; 95% CI: 71%, 93%) [11]. Sequences uploaded to
163 GISAID from the public health laboratory in Hong Kong indicated clade 5a.2a was circulating
164 from March 2024. The WHO vaccine recommendation for influenza A(H1N1) changed clade
165 from 5a.2a for the 2022/23 season to 5a.2a.1 for the 2023/24 season. Influenza A(H1N1)
166 strains detected in Europe were more similar to the 2023/24 vaccine strain which may
167 contribute to the higher VE estimated there.

168

169 Influenza B circulated at relatively low levels throughout the season. We estimated a VE
170 against influenza B as 66% (42%, 80%). Estimates from the US NVSN outpatients reported a
171 similar estimate for children of 64% (95% CI: 47%, 75%), but another three US outpatient
172 networks reported higher VE against influenza B for children of 79% (95% CI: 71, 85;
173 VISION), 89% (95% CI: 70, 97; US Flu VE) [10], and 79% (95% CI: 76%, 82%; California) [13].
174 Surveillance networks in Europe and Canada did not report a VE estimate against influenza B
175 due to small sample sizes [11,12].

176

177 Hong Kong has experienced a longer period of influenza circulation in the 2023/24 season,
178 lasting 28 weeks from mid-January [14] compared to 12 to 14 weeks for the same period in
179 previous years [15], or compared to an average of 22 weeks for the 2013/14 to 2018/19
180 influenza seasons [16] that included circulation before January. Disruption to influenza
181 seasonality after the COVID-19 pandemic has been reported elsewhere [17,18]. Whether or
182 how quickly influenza patterns will return to pre COVID-19 seasonality remains to be seen.

183

184 Influenza vaccination coverage in Hong Kong has been higher in the 2023/24 season
185 compared to previous seasons, with 49% of children under 6 years of age and 68% of

186 children 6 to 12 years of age vaccinated this year [1]. This is an increase from 38% and 60%
187 in the 2022/23 season for the same age groups. Similarly, among the controls in our study
188 the vaccination coverage for children under 6 years and 6-12 years has increased from 8%
189 and 12% respectively in 2009 to 2014 [3], to 14% and 15% in 2015/16 [19], to 30% and 59%
190 in 2022/23 [6], and now to 43% and 70% in this study. In particular, influenza vaccine uptake
191 in children has increased very substantially since the introduction of school-based
192 vaccination in 2018/19 [1]. We estimated the direct effect of vaccination, but this school-
193 based vaccination program may also have indirect benefits to unvaccinated and vaccinated
194 children by reducing the overall prevalence of infection.

195

196 Some limitations of our study include a small sample size when stratifying estimates by age
197 group resulting in low precision, particularly for the older age group which experienced
198 fewer hospitalizations. Second, multiplex rapid antigen tests that detect several respiratory
199 viruses including influenza are now readily available in Hong Kong [20] which could impact
200 hospitalization rates if parents sought care or were prescribed antivirals based on timely
201 rapid test results. Use of rapid tests might also be correlated with receipt of vaccination. In
202 both scenarios, the use of rapid tests may alter healthcare seeking behavior and cause
203 selection bias in test-negative studies.

204

205 In conclusion, during a prolonged influenza season in Hong Kong we estimated influenza VE
206 against hospitalizations during a 17-week influenza A(H3N2) epidemic as 55% (95% CI: 30%,
207 72%) and during a 17-week influenza A(H1N1) epidemic as 54% (95% CI: 33%, 69%).

208 Influenza B circulated throughout and the VE against influenza B was 66% (95% CI: 42%,
209 80%). School-based vaccination has led to increases in influenza vaccination coverage in

210 children and reduced the burden of influenza-associated hospitalizations in children in Hong

211 Kong.

212

213

214 **ACKNOWLEDGMENTS**

215 The authors thank colleagues at Queen Mary Hospital and Princess Margaret Hospital for
216 facilitating participant enrolment. The authors thank Julie Au for technical support.

217

218 **FUNDING**

219 This research was financially supported by a grant from the Health and Medical Research
220 Fund, Health Bureau, the Government of the Hong Kong Special Administrative Region
221 (grant number INF-HKU-3). BJC is supported by the National Institute of Allergy and
222 Infectious Diseases, National Institutes of Health, Department of Health and Human
223 Services, under contract no. 75N93021C00015, the Theme-based Research Scheme (grant
224 number T11-712/19-N) of the Research Grants Council of the Hong Kong SAR Government,
225 and an RGC Senior Research Fellowship from the University Grants Committee (grant
226 number HKU SRFS2021-7S03).

227

228 **POTENTIAL CONFLICTS OF INTEREST**

229 BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Novavax, Pfizer, Roche,
230 and Sanofi Pasteur. SGS has consulted for Moderna, Novavax, Pfizer, Evo Health, and CSL
231 Seqirus. The authors report no other potential conflicts of interest.

232

233

234 **REFERENCES**

- 235 [1] Centre for Health Protection, Government of the Hong Kong SAR. Statistics on
236 Vaccination Programmes in the Past 3 years 2024.
237 <https://www.chp.gov.hk/en/features/102226.html> (accessed July 11, 2024).
- 238 [2] Wong WH-S, Peare S, Lam HY, Chow CB, Lau YL. The estimated age-group specific
239 influenza vaccine coverage rates in Hong Kong and the impact of the school outreach
240 vaccination program. *Hum Vaccin Immunother* 2022;18:1–5.
- 241 [3] Cowling BJ, Chan K-H, Feng S, Chan ELY, Lo JYC, Peiris JSM, et al. The effectiveness of
242 influenza vaccination in preventing hospitalizations in children in Hong Kong, 2009-
243 2013. *Vaccine* 2014;32:5278–84.
- 244 [4] Chua H, Kwan MYW, Chan ELY, Wong JSC, Peiris JSM, Cowling BJ, et al. Influenza vaccine
245 effectiveness against influenza-associated hospitalization in children in Hong Kong,
246 2010-2020. *Vaccine* 2021;39:4842–8.
- 247 [5] Xiong W, Cowling BJ, Tsang TK. Influenza Resurgence after Relaxation of Public Health
248 and Social Measures, Hong Kong, 2023. *Emerg Infect Dis* 2023;29:2556–9.
- 249 [6] Cowling BJ, Kwan MYW, Murphy C, Chan ELY, Wong JSC, Sullivan SG, et al. Influenza
250 Vaccine Effectiveness Against Influenza-Associated Hospitalization in Hong Kong
251 Children Aged 9 Months to 17 Years, March-June 2023. *J Pediatric Infect Dis Soc*
252 2023;12:586–9.
- 253 [7] Murphy C, Kwan MYW, Chan ELY, Wong JSC, Sullivan SG, Peiris M, et al. Influenza
254 vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in
255 Hong Kong children aged 9 months to 17 years, June-November 2023. *Vaccine*
256 2024;42:1878–82.
- 257 [8] Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, et al.

- 258 Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the
259 Advisory Committee on Immunization Practices - United States, 2022-23 Influenza
260 Season. *MMWR Recomm Rep* 2022;71:1–28.
- 261 [9] Doll MK, Pettigrew SM, Ma J, Verma A. Effects of Confounding Bias in Coronavirus
262 Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs
263 Due to Correlated Influenza and COVID-19 Vaccination Behaviors. *Clin Infect Dis*
264 2022;75:e564–71.
- 265 [10] Frutos AM, Price AM, Harker E, Reeves EL, Ahmad HM, Murugan V, et al. Interim
266 Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States. *MMWR*
267 *Morb Mortal Wkly Rep* 2024;73:168–74.
- 268 [11] Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, et al. Interim 2023/24
269 influenza A vaccine effectiveness: VEBIS European primary care and hospital
270 multicentre studies, September 2023 to January 2024. *Euro Surveill* 2024;29.
271 <https://doi.org/10.2807/1560-7917.ES.2024.29.8.2400089>.
- 272 [12] Skowronski DM, Zhan Y, Kaweski SE, Sabaiduc S, Khalid A, Olsha R, et al. 2023/24 mid-
273 season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the
274 Canadian Sentinel Practitioner Surveillance Network (SPSN). *Euro Surveill* 2024;29.
275 <https://doi.org/10.2807/1560-7917.ES.2024.29.7.2400076>.
- 276 [13] Zhu S, Quint J, León TM, Sun M, Li NJ, Tenforde MW, et al. Interim Influenza Vaccine
277 Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-
278 January 2024. *MMWR Morb Mortal Wkly Rep* 2024;73:175–9.
- 279 [14] Centre for Health Protection, Government of the Hong Kong SAR. CHP announces end
280 of influenza season 2024.
281 <https://www.info.gov.hk/gia/general/202407/25/P2024072500406.htm> (accessed

282 August 23, 2024).

283 [15] Centre for Health Protection, Government of the Hong Kong SAR. COVID-19 & Flu

284 Express Volume 2, Number 28 (published on Jul 18, 2024) 2024.

285 https://www.chp.gov.hk/files/pdf/covid_flux_week28_18_7_2024_eng.pdf (accessed

286 August 23, 2024).

287 [16] Wong N-S, Leung C-C, Lee S-S. Abrupt Subsidence of Seasonal Influenza after COVID-19

288 Outbreak, Hong Kong, China. *Emerg Infect Dis* 2020;26:2753–5.

289 [17] Skowronski DM, Chuang ES, Sabaiduc S, Kaweski SE, Kim S, Dickinson JA, et al. Vaccine

290 effectiveness estimates from an early-season influenza A(H3N2) epidemic, including

291 unique genetic diversity with reassortment, Canada, 2022/23. *Euro Surveill* 2023;28.

292 <https://doi.org/10.2807/1560-7917.ES.2023.28.5.2300043>.

293 [18] Wang MH, Hu ZX, Feng LZ, Yu HJ, Yang J. [Epidemic trends and prevention and control

294 of seasonal influenza in China after the COVID-19 pandemic]. *Zhonghua Yi Xue Za Zhi*

295 2024;104:559–65.

296 [19] Cowling BJ, Kwan MYW, Wong JSC, Feng S, Leung C-W, Chan ELY, et al. Interim

297 estimates of the effectiveness of influenza vaccination against influenza-associated

298 hospitalization in children in Hong Kong, 2015-16. *Influenza Other Respi Viruses*

299 2017;11:61–5.

300 [20] Murphy C, Mak L, Cheng SMS, Liu GYZ, Chun AMC, Leung KKY, et al. Diagnostic

301 performance of multiplex lateral flow tests in ambulatory patients with acute

302 respiratory illness. *Diagn Microbiol Infect Dis* 2024;110:116421.

303

304

305 **FIGURE LEGEND**

306

307 Figure 1. Number of children admitted to hospital and enrolled in this study from November
308 2023 to June 2024. The 2023-24 influenza A(H3N2) and influenza A(H1N1) epidemics were
309 specified by the number of weekly hospitalizations and are indicated using brackets.

310

311

312 Table 1. Characteristics of children hospitalized and enrolled in this study.

Variable	Influenza positive (n=709)	Influenza negative and SARS-CoV-2 negative (n=3658)	p-value
Male n (%)	410 (57.8)	2015 (55.1)	0.192
Age group n (%)			
9 months to 3 years	264 (37.2)	1292 (35.3)	<0.001
4 to 8 years	261 (36.8)	1610 (44.0)	
9 to 17 years	184 (26.0)	756 (20.7)	
Underlying medical conditions			
Lung diseases	17 (2.4%)	198 (5.4%)	0.379
Cardiac diseases	3 (0.4%)	18 (0.5%)	
Other	4 (0.6%)	30 (0.8%)	
Receipt of influenza vaccine n (%)			
9 months to 3 years	39 (14.8)	466 (36.1)	0.003
4 to 8 years	117 (44.8)	1119 (69.5)	
9 to 17 years	78 (42.4)	492 (65.1)	
All ages	234 (33.0)	2077 (56.8)	

313

314

Table 2: Influenza vaccine effectiveness estimates against hospitalization associated with influenza A(H3N2), A(H1N1) and B, overall and stratified by age.

	Total	Influenza positive by PCR			Influenza negative and SARS-CoV-2 negative by PCR			Vaccine Effectiveness*	
		n vac	N	%	n vac	N	%	%	95% CI
Influenza A(H3N2)[†]	2119	70	178	39.3	1055	1941	54.4	55.4	29.6 to 71.8
Age stratified									
9 months to 3 years	794	10	59	16.9	250	735	34.0	60.3	13.0 to 81.9
4 to 8 years	922	43	80	53.8	581	842	69.0	55.9	13.9 to 77.4
9 to 17 years	403	17	39	43.6	224	364	61.5	27.0	-149.5 to 78.7
Influenza A(H1N1)[‡]	2465	97	287	33.8	1308	2178	60.1	54.4	33.4 to 68.8
Age stratified									
9 months to 3 years	848	21	130	16.2	280	718	39.0	60.1	31.8 to 76.6
4 to 8 years	1075	47	110	42.7	691	965	71.60	66.2	34.6 to 82.5
9 to 17 years	542	29	47	61.7	337	495	68.1	26.2 [¶]	-39.0 to 60.8
Influenza B[§]	3822	38	164	22.4	2077	3658	56.8	66.1	42.2 to 80.1
Age stratified									
9 months to 3 years	1343	3	51	5.9	466	1292	36.1	84.1	45.8 to 95.3

4 to 8 years	1657	17	47	36.2	1119	1610	69.5	58.2	-2.1 to 82.9
9 to 17 years	822	18	66	27.3	492	756	65.1	44.7	-62.4 to 81.2

*Adjusted for age, sex, prior vaccination and underlying conditions

[†]Influenza A(H3N2) VE was estimated during the period 19 November 2023 to 23 March 2024

[‡]Influenza A(H1N1) VE was estimated during the period 25 February to 12 June 2024

[§]Influenza B VE was estimated during the period 16 November 2023 to 12 June 2024

[¶]Adjusted for age, sex and underlying conditions but not for prior vaccination status due to insufficient sample size

